Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Durrington

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Journal of Clinical Lipidology|December 3, 2010
Proteinuria and severe mixed dyslipidemia associated with a novel APOAV gene mutationHandrean Soran, Valentine Charlton-Menys, Robert Hegele, et al.
Clinical Endocrinology|June 10, 2005
The effect of atorvastatin on serum lipoproteins in acromegalyManoj Mishra, Paul Durrington, Mike Mackness, et al.
Clinical Therapeutics|September 23, 2008
Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registriesRoberta Ara, Abdullah Pandor, Indra Tumur, et al.
Pharmacoeconomics|March 13, 2017
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalChristopher Carroll, Paul Tappenden, Rachid Rafia, et al.
Pharmacoeconomics|November 17, 2016
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalChristopher Carroll, Paul Tappenden, Rachid Rafia, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 23, 2009
Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov modelRoberta Ara, Abdullah Pandor, Indra Tumur, et al.
International Journal of Cardiology|August 12, 2016
Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomesPrakash C Deedwania, Terje R Pedersen, David A DeMicco, et al.
Atherosclerosis|December 4, 2003
Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemiaMuriel J Caslake, Grace Stewart, Stephen P Day, et al.
European Journal of Endocrinology|January 22, 2013
Atorvastatin administration is associated with dose-related changes in IGF bioavailabilityRam P Narayanan, Matthew Gittins, Kirk W Siddals, et al.
BMJ Open|July 29, 2020
Predicting major adverse cardiovascular events for secondary prevention: protocol for a systematic review and meta-analysis of risk prediction modelsRalph K Akyea, Jo Leonardi-Bee, Folkert W Asselbergs, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Journal of Clinical Lipidology|December 3, 2010
Proteinuria and severe mixed dyslipidemia associated with a novel APOAV gene mutationHandrean Soran, Valentine Charlton-Menys, Robert Hegele, et al.
Clinical Endocrinology|June 10, 2005
The effect of atorvastatin on serum lipoproteins in acromegalyManoj Mishra, Paul Durrington, Mike Mackness, et al.
Clinical Therapeutics|September 23, 2008
Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registriesRoberta Ara, Abdullah Pandor, Indra Tumur, et al.
Pharmacoeconomics|March 13, 2017
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalChristopher Carroll, Paul Tappenden, Rachid Rafia, et al.
Pharmacoeconomics|November 17, 2016
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalChristopher Carroll, Paul Tappenden, Rachid Rafia, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 23, 2009
Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov modelRoberta Ara, Abdullah Pandor, Indra Tumur, et al.
International Journal of Cardiology|August 12, 2016
Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomesPrakash C Deedwania, Terje R Pedersen, David A DeMicco, et al.
Atherosclerosis|December 4, 2003
Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemiaMuriel J Caslake, Grace Stewart, Stephen P Day, et al.
European Journal of Endocrinology|January 22, 2013
Atorvastatin administration is associated with dose-related changes in IGF bioavailabilityRam P Narayanan, Matthew Gittins, Kirk W Siddals, et al.
BMJ Open|July 29, 2020
Predicting major adverse cardiovascular events for secondary prevention: protocol for a systematic review and meta-analysis of risk prediction modelsRalph K Akyea, Jo Leonardi-Bee, Folkert W Asselbergs, et al.
Pageof 5